May 8, 2015 8:52 am Published by

Founded in 2009, Kymab is the first spin-out from The Wellcome Trust Sanger Institute, Cambridge, U.K. a world leader in the Human Genome Project and genetic studies to determine the function of genes in health and disease.

Kymab has developed a novel approach to the generation of fully human monoclonal antibody therapeutics via its proprietary Kymouse™ platform. Kymab aims to evolve into a world leading biopharmaceutical company through the use of its platform to build a drug pipeline.

Antibody-based biopharmaceuticals represent one of the most medically relevant and commercially successful areas of drug development. Annual global sales of the antibodies are forecast to reach approximately $100 billion in 2017. Innovative platforms to discover novel antibodies are therefore of significant strategic importance to larger pharma companies but also enable in-house efforts to rapidly assemble a high value drug pipeline, particularly in the immuno-oncology space.

The Kymouse™ platform is capable of rapidly generating a very broad and diverse range of fully human antibodies against multiple challenging, and previously intractable, disease targets. Kymouse™ has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding a rare drug candidate with best-in-class characteristics. The precision engineering of the Kymouse™ platform using insertion technology, not random transgenesis, generates very high affinity, candidate-quality molecules without need for further lead optimisation.

In addition to the Kymouse™ platform, Kymab has two additional technologies to advance the discovery of fully human monoclonal antibody drugs (MAB’s):

  • A B-cell screening platform that deeply mines the Kymouse™ and isolates candidate-quality molecules
  • Its knockout platform that enables rapid knockout of drug targets from Kymouse™ strains to pursue difficult and highly homologous sequences.

Kymab is building a rich pipeline of assets in three therapeutic spaces: immuno-oncology, immunology and opportunistic (including but not limited to chronic pain, infectious disease and haematology/chronic anaemia)

Categorised in:

This post was written by source